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Abstract
Objective: To assess 2009 A(H1N1) seroconversion rates and their determinants within an unvaccinated population in
Vientiane Capital, Laos.
Methods: CoPanFlu Laos, a general population cohort of 807 households and 4,072 participants was established in March
2010. Sociodemographic data, epidemiological data, and capillary blood samples were collected from all the household
members in March, and again in October 2010, in order to assess the level of antibodies to 2009 A(H1N1) with the
haemagglutination inhibition assay. 2009 A(H1N1) seroconversion was defined as a fourfold or greater increase in titre
between inclusion and follow-up. Determinants for pandemic influenza infection were studied using the generalized
estimating equations model, taking household clustering into account.
Results: Between March and November 2010, 3,524 paired sera were tested. Prior to the pandemic, our cohort was almost
completely vaccine-naive for seasonal influenza. The overall seroconversion rate among nonvaccinated individuals
(n= 2,810) was 14.3% (95%CI [13.0, 15.6]), with the highest rate for participants under 20 yo (19.8%, 95%CI [17.4, 22.4]) and
the lowest rate for participants over 60 yo (6.5%, 95%CI [3.7, 10.4]). Participants with lower baseline titres had significantly
higher infection rates, with a dose-effect relationship. Odds ratios (ORs) ranged from 76.5 (95%CI [27.1, 215.8]), for those
with a titre at inclusion of 1:10, to 8.1 (95%CI [3.3, 20.4]), for those with a titre of 1:40. Having another household member
with a titre $1:80 was associated with a higher likelihood of immunity (OR= 3.3, 95%CI [2.8, 3.9]).
Conclusion: The determinants and age distribution for seroconversion within a vaccine-naive population were similar to
those found in developed countries. This pandemic was characterized by strong epidemiological determinants, regardless
of geographical zone and level of development. Moreover, we detected pre-existing cross-reacting antibodies in
participants over 60 yo, which could not have originated from former multiple vaccination as has been suggested
elsewhere.
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Introduction
Epidemiological information on influenza in tropical countries
traditionally remains limited, compared with temperate countries
[1]. However, since 2003, the situation has changed dramatically
in Asia-Pacific, especially Southeast Asia, as this region is regarded
as a potential epicentre of the next pandemic [2]. In Laos, in
response to concerns over avian influenza A(H5N1), national
governance on pandemic preparedness has been developed [2],
and laboratory-based influenza surveillance has been implemented
in the capital city of Vientiane [3].
This surveillance system provided useful information about the
spread of 2009 influenza A(H1N1) pandemic virus (2009
A(H1N1)). The first case in the Lao People’s Democratic Republic
(PDR) was confirmed on 16 June 2009, by the National Centre for
Laboratory and Epidemiology (NCLE) in Vientiane Capital [4].
Between 28 April 2009 and 1 June 2010, the NCLE confirmed
663 cases of influenza, including 335 cases that tested positive for
pandemic virus (50.5%), the remaining cases (49.5%) being
variations of seasonal influenza [5], mostly A(H3) virus (NCLE
data, unpublished). Pandemic cases were reported in 13 of the
country’s 17 provinces, but were mainly recorded in Vientiane
Capital and Vientiane Province, in the south and centre of the
country. Two deaths associated with pandemic virus infection
were identified. Since July 2010, biological investigations of
pandemic influenza virus, and epidemiological reporting have
been limited. However, data collected from neighbouring coun-
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tries in Southeast Asia suggest that the pandemic virus continues to
circulate, and that the number of confirmed cases does not reflect
the true number of infections [5].
In order to investigate the burden of 2009 A(H1N1) influenza
within the general population of Vientiane Capital, we set out to
assess 2009 A(H1N1) seroconversion rates and their determinants
within a cohort of households, implementing the first ever sero-
epidemiological investigation of influenza in Laos. In this article,
we report the results of the first two phases of this programme in a
population that was virtually vaccine-naı¨ve for influenza, insofar as
influenza vaccine was not routinely available in the country prior
to the pandemic [3].
Materials and Methods
Ethics Statement
Approval was obtained from the Lao National Ethics Commit-
tee for Health Research in Lao PDR (266/NECHR; 23 October
2009). All participants provided their written informed consent.
Parents or legal guardians were asked to sign on behalf of children
under 17 yo.
Study design and population
The Cohort for Pandemic Influenza in Laos (CoPanFlu-Laos)
was established as part of the CoPanFlu International Consortium
research programme. This programme was implemented in the
wake of the influenza pandemic alert in April 2009, in order to
study the epidemiological, environmental and virological determi-
nants of influenza infection in different regions of the world (i.e.,
metropolitan France [6], the Indian Ocean [7], Africa [8], South
America and Southeast Asia).
Cohort study. The Laotian study was conducted within the
administrative boundaries of the Vientiane metropolitan area. The
household cohort was established on the basis of a pre-existing
sample constituted for the "Urbanization, Governance and Spatial
Disparities of Health in Vientiane’’ research programme [9–11].
Households were recruited in 27 neighbourhoods, distributed
across three zones: (i) the central zone; (ii) the inner urbanized belt
and (iii) the outer urbanized belt, in order to reflect the variability
of Vientiane’s overall population [10].
Households were only included in the study if all the members
agreed to take part (consent for children aged 16 or under had to
be provided by their parents). A household was defined as a group
of individuals living on the same plot of land (one or more houses)
or in the same building (apartment) and sharing their meals.
Figure 1. Flowchart of inclusion and follow-up phases.
doi:10.1371/journal.pone.0061909.g001
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The inclusion visit (March–April 2010) was organized as
follows: a team of interviewers visited the household at an
appointed date in order to present the project, collect the written
consent forms from each household member, identify a ‘‘referent’’
household member, collect inclusion information and draw the
blood samples. If any household member refused to take part, the
household was not included in the study. The questionnaires
collected information on the participants’ demographics, work
environment, general health status, history of influenza-like
illnesses (ILIs) and other chronic and acute diseases, their history
of vaccination, living conditions and household environment.
A capillary blood sample was systematically collected from each
member of the household with a single-use automatic lancing
device, and taken to the Centre d’Infectiologie Christophe
Me´rieux of Lao PDR (CICML) for centrifugation, aliquoting
and storage at 280 uC.
The follow-up phase (October–November 2010), consist-
ed of a systematic visit to each household in order to take a second
capillary blood sample from each member, using the same
methodology as at the inclusion visit, and to update the
demographic, environmental and clinical data.
See Figure 1 for the study’s flowchart at inclusion and follow-up.
Prepandemic data. The Lao Red Cross (LRC) blood bank
provided 1,000 plasma samples that had been collected in 2008
from donors aged 17–58 years living in Vientiane Capital. These
samples were used to investigate the presence of antibodies to 2009
A(H1N1) in the population before the pandemic. These samples
came from blood donations that were suitable for transfusion (i.e.,
testing negative for the human immunodeficiency virus, the
hepatitis B and C viruses, and syphilis). Information about age and
sex was available for these samples.
Expected number of participants and
justification. Based on the hypothesis of a 30% attack rate,
we calculated that a follow-up of 731 households in Vientiane
Capital, Lao PDR (estimated to total around 3,000 persons) would
ensure statistical power above 80% and allow us to identify the risk
factors for exposure levels of 10–90% and a relative risk greater
than 1.4.
Laboratory methods
A standard haemagglutination inhibition (HI) technique was
performed to detect and quantify antibodies to the 2009 A(H1N1)
virus, as detailed elsewhere [7,8,12]. Twofold serum dilutions
(1:10–1:1280) were tested using a fully automated protocol. The
HI titre was determined as the last dilution providing complete
inhibition of haemagglutination. All the analyses were performed
in the presence of a serum agglutinating activity control and the
same negative and positive controls, the latter including sera with
titres ranging from 1:10 to 1:1280.
Data analysis and statistics
All the serological data were analyzed according to the
participants’ pandemic virus vaccination status. Nine participants
who were vaccinated against nonpandemic virus (i.e., seasonal
prepandemic influenza strains) between March and October 2010
were excluded from the analysis. These participants belonged to
six different households (two in the inner urbanized belt, four in
the outer rural belt). None of the participants seroconverted for
pandemic influenza. Six of them were women, and their median
age was 44.5 yo [range: 22.4–58.6].
Seroprevalence of 2009 A(H1N1) antibodies at a given HI titre
was calculated as the percentage of samples with an antibody titre
equal to or above the threshold titre under consideration.
Seroconversion was defined as a fourfold or greater increase in
antibody titres.
In order to compare seroprevalence between blood donors
sampled in 2008 and the participants included in the cohort in
2010, individuals were matched for age (62 years) and sex using
the greedy algorithm, with the %GMATCH macro in SASH
version 9.1.3 (SAS Institute Inc., Cary, NC). Differences in
seroprevalence between matched individuals were assessed with
the McNemar chi-square test for matched pairs.
GMTs were calculated by assigning a titre of 5 to specimens in
which no HI antibody was detected. The following log transfor-
mation was used: log HI titre = log2 (HI titre/5). The maximum
likelihood estimate of the GMT of truncated HI titres and its 95%
confidence interval were obtained by means of a statistical
technique based on survival analysis, using PROC LIFEREG in
SASH version 9.1.3 (SAS Institute Inc., Cary, NC), avoiding
underestimation for censored observations [13].
A generalized estimating equations (GEE) model was used to
identify factors associated with seroconversion, taking household
clustering into account. This analysis included 2,810 nonvacci-
nated participants (720 households) for whom full inclusion and
follow-up information was available regarding age, serology results
and selected risk factors. A univariate screening analysis was run
on all the variables. Variables associated with seroconversion with
a p value #0.2 were included in the multivariate regression model.
Results
Characteristics of the sample
Between 11 March 2010 and 11 April 2010, we recruited 4,072
individuals belonging to 807 households. The main characteristics
of the cohort at inclusion are set out in Table 1 for households and
Table 2 for participants. Participants for whom we were able to
collect serum samples at inclusion and follow-up (n = 3,524) had a
median age of 28.1 years (range: 0.7, 90.6) and 54% (n = 1,902)
were women. In all, 207 households (33.1%) were located in the
central zone of Vientiane Capital, 216 (26.8%) in the inner
urbanized belt and 324 (40.1%) in the outer urban belt. A total of
23% of participants (n = 714) were vaccinated against influenza in
2010, of whom 98.7% (n = 705) were vaccinated against pandemic
influenza (Influenza A (H1N1) 2009 Monovalent Vaccine, CSL
Limited, nonadjuvanted).
Table 1. Characteristics of the recruited households at
inclusion.
Household description (N=807)
Level of urbanization*
- Central zone 3.1%)
- Inner urbanized belt 216 (26.8%)
- Outer urbanized belt 324 (40.1%)
Number of individuals per household (mean 6 SD) 5.062.21
Number of children per household (mean 6 SD) 1.3561.19
Number of rooms per household (mean 6 SD) 2.961.33
Ethnic origin: Lao Lum 789 (97.8%)
*according to Valle´e et al., Emerging themes in epidemiology. 2007.
doi:10.1371/journal.pone.0061909.t001
CoPanflu Laos Study
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Seroprevalence at inclusion in nonvaccinated
participants (n = 2,810)
Table 3 and Figure 2 show the results of the HI analyses for
each age group. For thresholds of either 1:40 (Table 3a), or 1:80
(Table 3b), the distribution of seroprevalence at inclusion followed
a U curve, with the highest prevalence for those below 20 yo and
over 60 yo. GMT values followed a similar pattern (Table 3c,
Fig. 2).
Comparison with prepandemic data (n = 841)
In order to compare seroprevalence between the pre- and post-
pandemic periods, 841 samples collected from blood donors in
2008 in Vientiane Capital were matched for age and sex with the
participants in our cohort. Prevalence and GMT values for these
blood donors were high (HI$1:80 = 18.8%, 95% CI [16.2, 21.4];
GMT = 45, 95% CI [43.4, 46.7]). In the prepandemic population,
the prevalence in the 17–19 age group (HI$1:80 = 18.7%, 95%
CI [15.0, 22.5]) was no higher than it was in the 20–58 group
(HI$1:80 = 18.9%, 95% [CI 15.1, 22.6]). A significant increase
between 2008 and 2009 could still be detected in the 17–19 yo
group (p = 0.01) with a threshold of 1:80.
Serological changes between inclusion and follow-up in
nonvaccinated participants (n = 2,810)
The period between the collection of inclusion (March 2010)
and follow-up (October 2010) samples within the CoPanFlu Laos
cohort encompassed the second epidemiological episode of 2009
A(H1N1) infections in Laos (see Fig. 3).
The overall analysis of the nonvaccinated participants
(n = 2,810) revealed a significant increase in seroprevalence at
the thresholds of 1:40 ((D$1:40 = 3.4, p = 0.0018; Table 3a) and
1:80 (D$1:80 = 13.4, p,0.0001; Table 3b), and the level of HI
antibodies was higher in October than it had been in March 2010
(DGMT = 7.5, p,0.0001; Table 3c). All estimates of the attack
rate (i.e., D$1:40, D$1:80, seroconversion rate (SCR), Tables 3
and 4) yielded the highest numbers in the 0–19 yo age group, and
the lowest in the over 60 yo group.
The overall SCR amongst nonvaccinated individuals was
14.3% (95% CI [13.0, 15.6]), with a significant difference
(p,0.0001) between participants under 20 yo (19.8%, 95% CI
[17.4, 22.4]) and over 60 yo (6.5%, 95% CI [3.7, 10.4]). In the 20–
59 yo group, 11.6% (95% CI [10.1, 13.3] seroconverted – a
significantly higher proportion than in the over 60 yo group
(p = 0.02) and a significantly lower one than in the under 20 yo
group (p,0.0001).
Figure 4 shows the proportions of the samples at inclusion and
follow-up that were equal to or above each titre level for the 0–19
yo, 20–39 yo, 40–59 yo and$60 yo age groups. Participants under
20 yo showed significant differences between inclusion and follow-
up for all titre levels between 1:40 and 1:160. Intermediate age
groups showed significant differences for titres 1:80 and 1:160. No
difference was observed at any titre level in individuals over 60 yo.
Determinants of seroconversion in nonvaccinated
participants (n = 2,810)
The data we had collected on the demographics, work
environment, general health status, history of ILIs and other
chronic and acute diseases, history of vaccination, living conditions
and household environment of participants living in the three
different areas of Vientiane Capital (central zone, inner urbanized
belt and outer urbanized belt), were analyzed using the GEE
model to identify factors associated with seroconversion.
After adjustment and tests for interactions, the final GEE
multivariate model identified four independent determinants for
seroconversion (see Table 5):
(i) Youth(,20 yo), was found to be a determinant, with an odds
ratio (OR) of 3.8, 95% CI [1.9, 7.8] (p = 0.0002), taking age$60 yo
as a reference;
(ii) An HI titre at inclusion,1:80 was a risk factor, with a dose-
effect relationship (OR ranging from 76.5, 95% CI [27.1, 215.8],
for a titre at inclusion equal to 1:10, to 8.1, 95% CI [3.3, 20.4] for
a titre of 1:40);
(iii) The presence in the household of one or several
seroconverted individuals was also a risk factor (OR = 3.3, 95%
CI [2.8, 3.9], p,.0001);
(iv) All other things being equal, a large household was a
protective factor (OR = 0.8, 95% CI [0.8, 0.9], p,.0001).
Serological changes between inclusion and follow-up in
participants vaccinated against 2009 A(H1N1) virus
(n = 705)
The vaccination rate varied across age groups. Children (0–19
yo) were less likely to be vaccinated than older participants (12.6%,
95% CI [10.7, 14.6] vs. 24.3%, 95% CI [22.5, 26.1]; p,0.0001).
The overall SCR for vaccinated participants was 26.4%, 95% CI
[23.2, 29.8] (n = 186). Tables 6, 7 and Figure 5 show the SCRs and
changes in GMT for each age group. Both SCRs and GMT
increases were significantly lower in individuals over 60 yo than in
the other age groups (p = 0.01 for SCRs and p = 0.03 for GMTs).
Table 2. Characteristics of the recruited individuals at
inclusion.
CoPanFlu cohort (N=4,072)
Median age (range) 26.5 [0.1–94.5]
Female 2,183 (53.6%)
Able to read and write (participants$16 yo) 2,800 (93.6%)
Students 1,348 (33.1%)
In employment 1,769 (43.4%)
Chronic disease 473 (11.6%)
Main chronic diseases reported
- High blood pressure 210 (5.2%)
- Gastralgia 158 (3.9%)
- Diabetes 74 (1.8%)
- Asthma 37 (0.9%)
History of acute diseases
- Dengue 385 (9.5%)
- Malaria 314 (7.7%)
- Pneumonia 73 (1.8%)
- Tuberculosis 5 (0.1%)
Body mass index (mean 6 SD) 21.765.0
History of influenza over past three years 165 (4.1%)
Influenza vaccination in 2009 22 (0.5%)
Pneumococcal vaccination 7 (0.2%)
Current smoker 481 (11.8%)
All the information (except BMI) was provided by the participants during the
inclusion interview.
doi:10.1371/journal.pone.0061909.t002
CoPanflu Laos Study
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Discussion
Deciphering the epidemiological characteristics and impact of
the 2009 influenza pandemic is an important public health
objective. It will lead to a better understanding of the public health
implications of influenza outbreaks, improvements in epidemio-
logical modelling, and more efficient management of future
influenza epidemics. Sero-epidemiological studies are the corner-
stone of strategies for estimating influenza attack rates in the
general population, as there are too many obstacles (e.g., presence
of asymptomatic or subclinical cases, wide disparities in healthcare
seeking behaviour) for clinical reporting systems to efficiently
account for all infected cases.
So far, most of the studies designed to record pandemic 2009
A(H1N1) attack rates have been based on cross-sectional
serological analyses. A clear limitation to the comparison of results
obtained in independent series is the significant variability in the
production of results, mostly due to differences in technical
protocols (e.g., antigen preparation, pre-analytic processing of
samples, choice of red blood cells) and endpoint analysis methods
[14–16]. The gold standard for providing sero-epidemiological
estimates of the attack rate is individual seroconversion studies, in
which blood samples are obtained before and after the epidemi-
ological episode under investigation, and which thus rely on pre-
existing cohorts. For obvious reasons, this constraint has limited
the number of studies based on individual seroconversion that
have been conducted on the 2009 A(H1N1) pandemic [7,8,17–
24], some of these studies being dedicated to specific populations
such as HIV patients or hospital staff.
Consequently, conducting general population-based studies
using individual paired samples collected before and after the
different waves of infection of the 2009 A(H1N1) variant is crucial
if we are to properly assess pandemic infection rates [25].
Seasonal patterns
Seasonal patterns in influenza activity in human populations in
East and Southeast Asia exist, but are not uniform across the
region. Periods of moderate to high activity typically last longer in
tropical and subtropical regions than in temperate ones, and occur
more frequently than once a year [26]. Both Cambodia and
Thailand seem to experience an influenza season between July and
December, with a peak during the rainy season [27,28]. Data from
the NCLE point to a similar trend in Laos, with year-round ILI
activity and a peak during the rainy season (May-October)
(unpublished results). This is illustrated in Figure 3, which shows
the ILI cases reported to the NCLE by three hospitals in Vientiane
Capital in 2008–2010, together with the chronology of the main
events regarding the pandemic influenza and the CoPanFlu Laos
study.
Haemagglutination Inhibition Assay
The HI analyses in our study indicating the proportions of the
samples at inclusion and follow-up that were equal to or above
each titre level in each age group suggest that titre of 1:80 may
represent the most relevant threshold for the specific diagnosis of
recent 2009 A(H1N1) infections (Fig. 4), consistent with previous
observations [8,12]. This is further supported by the fact that the
D$1:80 yielded an estimate of attack rate similar to that obtained
Figure 2. Seroprevalence, seroconversion rates and GMT in March and October 2010 in 2,810 nonvaccinated individuals. Error bars
represent confidence intervals. Spv: seroprevalence. Scr: seroconversion.$1:40: Seroprevalence analyzed with a cutoff$1:40.$1:80: Seroprevalence
analyzed with a cutoff$1:80. p value calculated using the McNemar chi-square for seroprevalence matched pairs. p value calculated using the
Wilcoxon signed rank test for GMT matched pairs.
doi:10.1371/journal.pone.0061909.g002
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from SCRs and illustrated by comparing the HI titres in each age
group at inclusion and follow-up. There is therefore a line of
evidence that the antibody level$1:80 was quite specific to
pandemic H1N1 infection. However, in a significant proportion of
the prepandemic samples, antibodies cross-reacting with the 2009
A(H1N1) antigen could be detected at titres of$1:40. Given the
cohort’s age range (17–58 yo), this finding probably denoted cross-
reactivity with recent seasonal flu strains, as observed in younger
age groups in developed countries [16,29]. The prevalence of a
pandemic HI titre$1:80 was also substantial in our prepandemic
samples, and was more unexpected, given the results of previous
analyses using the same technique [8,12]. The most probable
explanation is that that plasma samples were obtained from the
blood donors, whereas we collected serum samples from our
cohort. It could also be explained, however, by specific previous
exposure to influenza strains within the Laotian population or,
more specifically, within the control group, leading to a matching
bias.
First round of blood collection, March 2010
The study began in March 2010, after the first wave of 2009
A(H1N1) virus in Laos. The inclusion-sampling period took place
5 months after the previous 2009 ILIs peak (see Fig. 3). Since it has
been established that the 2009 A(H1N1) antibody titre could
decrease rapidly in certain individuals once the infectious episode
was over [7,12], the 2009 A(H1N1) seroprevalence data at
inclusion may underestimate the actual number of previous
infections.
Serological analysis provided a picture consistent with what has
been reported in other countries: whichever HI threshold was
considered, the highest prevalence levels and HI titres were
identified in (i) individuals under 20 yo, reflecting the fact that this
age group was the primary target of the pandemic virus
[7,8,12,17–19,30–38], and (ii) the elderly. Elderly individuals were
paradoxically poorly impacted by the first wave, most probably
because of pre-existing cross-reactive antibodies. They may have
been infected with Spanish flu-related A(H1N1) strains prior to the
major antigenic drift of A(H1N1) viruses that occurred at the end
of the 1940s [39]. These antibodies had been detected in
individuals over 60 yo in most previous sero-epidemiological
studies [7,8,17,30,32,38,40–52], with the exception of three studies
in China [53], Taiwan [19], and Singapore [54], where none of
the participants over 60 yo was seropositive for pandemic 2009
A(H1N1) antibodies.
It has been suggested that iterative vaccination against seasonal
influenza may provide another plausible explanation for the
presence of cross-reactive antibodies in the elderly [47,53,54],
because this age group benefits from the highest vaccine coverage
Table 3. Seroprevalence and GMT in March and October 2010 in 2,810 nonvaccinated participants.
Table 3a
HI$1:40
N March 2010 October 2010 D$1:401 p value*
All age groups 2,810 68.1% [66.3–69.8] 71.5% [69.8–73.1] 3.4 0.0018
00–19 yo 1,034 70.9% [68.0–73.6] 79.3% [76.7–81.7] 8.4 ,0.0001
20–39 yo 929 65.6% [62.4–68.6] 66.3% [63.2–69.4] 0.7 0.7
40–59 yo 613 64.6% [60.7–68.4] 65.4% [61.5–69.2] 0.8 0.7
60+yo 232 75.0% [68.9–80.4] 72.8% [66.6–78.5] 22.2 0.6
Table 3b
HI$1:80
N March 2010 October 2010 D$1:801 p value*
All age groups 2,810 20.4% [18.9–21.9] 33.8% [32.1–35.6] 13.4 ,0.0001
00–19 yo 1,034 27.8% [25.1–30.6] 48.6% [45.5–51.6] 20.8 ,0.0001
20–39 yo 929 15.5% [13.2–18.0] 25.4% [22.6–28.3] 9.9 ,0.0001
40–59 yo 613 12.9% [10.3–15.8] 24.1% [20.8–27.7] 11.2 ,0.0001
60+yo 232 26.7% [21.2–32.9] 27.2% [21.5–33.4] 0.5 0.9
Table 3c
GMT
N March 2010 October 2010 D GMT1 p value**
All age groups 2,810 42.4 [41.4–43.4] 49.9 [48.7–51.1] 7.5 ,0.0001
00–19 yo 1,034 46.6 [44.7–48.5] 60.2 [57.9–62.5] 13.6 ,0.0001
20–39 yo 929 39.5 [38.0–41.0] 44.0 [42.3–45.8] 4.5 ,0.0001
40–59 yo 613 38.5 [36.9–40.3] 43.8 [41.6–46.1] 5.3 ,0.0001
60+yo 232 46.6 [43.5–49.8] 47.0 [43.4–50.8] 0.4 0.9
*p value calculated using the McNemar chi-square for matched pairs. **p value calculated using the Wilcoxon signed rank test for matched pairs. 1Increases in
prevalence of HI titres$1:40 and$1:80 between inclusion and follow-up indicated as ‘‘D$1:40’’ and ‘‘D$1:80’’, respectively. Increase in geometric mean titres (GMTs)
between inclusion and follow-up indicated as ‘‘DGMT.
doi:10.1371/journal.pone.0061909.t003
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in developed countries. The current study does not support this
hypothesis, and suggests that this observed immunity is more likely
due to a natural pre-exposure to influenza strains since only one of
the participants over 60 yo enrolled in our study had previously
been vaccinated against seasonal influenza virus, and then only
once.
Comparison with prepandemic data
Our attempt to estimate prepandemic seroprevalence by
studying blood donors sampled in 2008 was not completely
satisfactory. The background noise observed in the results of
plasma samples made it hard to perform the relevant fine-tuned
comparisons, and we were thus only able to surmise that
individuals aged 17–20 years had been the major epidemiological
target of the first pandemic wave. A surrogate estimate of the
attack rate during the 2009 wave could be provided by analyzing
the distribution of low-and high-titre antibodies. After the first
wave of the pandemic, a high prevalence of antibodies was
observed (68.1%), including a large proportion of low titre
antibodies (47.7% of the studied population had an HI titre of
1:40). Some of these low-titre antibodies may have been acquired
during the first pandemic wave, but were indistinguishable from
Figure 3. Seasonal influenza-like illness activity and chronology of the pandemic events and CoPanFlu programme.
doi:10.1371/journal.pone.0061909.g003
Table 4. Seroconversion rates between March and October 2010 in 2,810 nonvaccinated participants.
Seroconversion rate in nonvaccinated participants
Individuals with inclusion HI titre,1:40 Individuals with inclusion HI titre$1:40 All groups
All age groups 30.3% [27.3–33.5] 6.7% [5.7–8.0] 14.3% [13.0–15.6]
00–19 yo 44.2% [38.5–50.0] 9.8% [7.8–12.2] 19.8% [17.4–22.4]
20–39 yo 24.1% [19.5–29.1] 4.3% [2.8–6.2] 11.1% [9.1–13.3]
40–59 yo 23.5% [18.0–29.7] 6.3% [4.1–9.2] 12.4% [9.9–15.3]
60+yo 17.2% [8.6–29.4] 2.9% [0.9–6.6] 6.5% [3.7–10.4]
doi:10.1371/journal.pone.0061909.t004
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cross-reactive antibodies acquired over time against a cocktail of
variants of influenza viruses that can differ from country to
country, reflecting different regional epidemiological histories. It is
worth noting that, in the case of Laos, at the time of inclusion, (i.e.,
after the 2009 wave), the distribution of HI titre at 1:40 across the
age groups was such that prevalence was lowest in individuals
younger than 20 yo, who were the major epidemiological target of
the first pandemic wave.
We were able to compare the Laotian data with data collected
in other population cohorts after the 2009 wave, using the same
HI technical protocol and the same interpretation criteria. In
Reunion Island, for instance, the prevalence of antibodies was
55% (33% with an HI titre of 1:40) [7], and in Mali the prevalence
of antibodies was 29% (13% with an HI titre of 1:40) [8]. In both
cases, the prevalence of antibodies at titres .1:40 (22% in
Reunion island and 16% in Mali) provided robust estimates of
strict seroconversion rates (i.e. 20% in Reunion island and 14% in
Mali). Similarly, in the case of Laos, the prevalence of antibodies
with titre .1:40 at the time of inclusion suggests that the attack
rate during the 2009 wave was in the order of 20% and confirms
the predominance of infection in those under the age of 20 (28%).
Different HI technical protocols implemented in different
studies can potentially compromise comparisons of results with
data yielded by the CoPanFlu Laos programme. Regarding the
specificity of the CoPanFlu HI protocol, if we consider a
seropositivity threshold of 1:80, the most relevant one for the
specific detection of 2009 A(H1N1) antibodies [12], Laotian rates
can be cautiously compared with those of other countries.
Figure 4. Distribution of samples at inclusion according to HI titre and age group. p value calculated using the McNemar chi-square for
matched pairs.
doi:10.1371/journal.pone.0061909.g004
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Estimated seroprevalence within the general population worldwide
following the first 2009 wave ranged from 3% in Norway [36] to
28% in Oceania [32]. Our seroprevalence results were close to
those observed in the USA [38], UK [33], and China [37], and
slightly lower than those observed in Oceania [30,32].
Serological changes between March 2010 and October
2010
In October 2010, six months after the first blood sample
collection round in the CoPanFlu cohort, a second round was
conducted within the cohort. This second round, coinciding with
Table 5. Determinants of seroconversion between March 2010 and October 2010 in nonvaccinated participants.
Determinants of seroconversion (n=2,810)
Odds ratio 95% CI p value
Age
00–19 yo 3.8 [1.9, 7.8] 0.0002
20–39 yo 1.5 [0.7, 3.1] 0.3
40–59 yo 1.6 [0.8, 3.3] 0.2
60+yo ref
HI at inclusion
1:10 76.5 [27.1, 215.8] ,.0001
1:20 27.8 [10.9, 70.5] ,.0001
1:40 8.1 [3.3, 20.4] ,.0001
$1:80 ref
No. seroconverted individuals in the household 3.3 [2.8, 3.9] ,.0001
Size of the household* 0.8 [0.8, 0.9] ,.0001
Generalized estimating equation multivariate model taking the cluster effect into account. *Size of the household included in the model as a discrete variable.
doi:10.1371/journal.pone.0061909.t005
Figure 5. Seroconversion rates and GMT in March and October 2010 in 705 vaccinated participants. Error bars represent confidence
intervals. Spv: seroprevalence. Scr: seroconversion.$1:40: Seroprevalence analyzed with a cutoff$1:40.$1:80: Seroprevalence analyzed with a
cutoff$1:80.
doi:10.1371/journal.pone.0061909.g005
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the start of the rainy season, lasted until early November 2010.
These two rounds encompassed the second epidemiological
episode of 2009 A(H1N1) in Laos (see Fig. 3), the follow-up
samples being obtained shortly after the influenza peak – a
favourable situation for optimized antibody detection. This gave us
the opportunity to analyze the serological results for paired
inclusion/follow-up samples and to obtain estimates of the attack
rates for each age group.
Comparisons of the serological data for the nonvaccinated
participants reinforced what had been observed in the first phase:
participants below 20 yo were clearly most heavily impacted by the
2009 A(H1N1) infection, with an SCR of 19%, while those over 60
yo were the least affected by the virus, with an SCR of 6.5%. The
D$1:80 observed between the two periods was fully consistent
with the SCR for the 0–59 yo groups, but underestimated the
attack rate amongst the elderly, probably owing to the seronega-
tion observed in this group between the two phases. By the end of
the second wave, it was estimated that as many as 50% of school-
aged children in Vientiane Capital had been infected. As observed
elsewhere, participants,20 yo were and remained the key target
of this pandemic during the second wave [17,36,40].
The impact of the second 2009 A(H1N1) wave has been less
extensively explored and, to our knowledge, no studies featuring
paired serum samples have so far been published on the subject.
Only three studies based on matched data have so far assessed the
impact of Wave 2 of the 2009 A(H1N1) virus, in Canada (Ontario)
[17], the UK (England) [40], and Norway [36]. The cumulative
incidence of infection we found was lower than the attack rates
reported in these three studies (26.3% in England, 27.6% in
Ontario and 43.3% in Norway).
Determinants of seroconversion
Our study included more than one hundred variables describing
the situation of each participant in terms of his or her geographical
location, demographics, work environment, general health status,
history of ILIs and other chronic and acute diseases, history of
vaccination, living conditions and household environment. The
final multivariate GEE model, taking household clustering into
account, identified only four independent determinants for
seroconversion. As expected, youth was found to be a strong
determinant of seroconversion, with an OR of 3.8, 95% CI [1.9,
7.8]. Our analysis also suggested that those with lower baseline
titres had significantly higher infection rates, with a clear dose-
effect relationship, with ORs ranging from 76.5 (95% CI [27.1,
215.8]), for those with an HI at inclusion of 1:10, to 8.1 (95% CI
[3.3, 20.4]), for those with an HI of 1:40. The two other
epidemiological determinants, corroborated in the literature, were
having another household member with a level of antibody
titre$80, which was associated with a higher likelihood of
immunity [23], and belonging to a large household, which
reduced the likelihood of being infected. This last result may
seem counterintuitive but is reminiscent of Cauchemez et al. ’s
finding [55,56]. These authors suggested that a ‘‘time-sharing’’
mechanism is at work for infection within the household: the
duration of contact between two members of a household can
basically be divided by the total number of household members.
Thus, the more crowded the household is, the less face-to-face
time one member spends with another, thereby decreasing
exposure times between individuals. However, as the authors
mentioned, the sociological, environmental, and biological mech-
anisms behind the relationship between secondary attack rates and
household size have yet to be elucidated.
A second explanation may be related to the specific structure of
Laotian households, which are far larger than the nuclear family.
They include members of the extended family, some of them
elderly. In Southeast Asia, the elderly fulfil a social function within
the household, for since they can no longer offer financial support,
land or other material goods, they provide childcare assistance and
Table 6. GMT in March and October 2010 in 705 vaccinated participants.
GMT in vaccinated participants
N March 2010 October 2010 D GMT p value*
All age groups 705 41.9 [40.0–43.8] 68.8 [65.5–72.0] 26.9 ,0.0001
00–19 yo 148 50.0 [44.9–55.5] 80.6 [72.0–89.6] 30.6 ,0.0001
20–39 yo 268 41.0 [38.1–44.1] 64.4 [59.6–69.4] 23.4 ,0.0001
40–59 yo 228 37.6 [34.8–40.6] 69.3 [63.8–75.0] 31.7 ,0.0001
60+yo 61 43.6 [38.0–49.6] 59.3 [51.5–67.6] 15.7 0.0003
*p value calculated using the Wilcoxon signed rank test for matched pairs.
doi:10.1371/journal.pone.0061909.t006
Table 7. Seroconversion rate between March and October 2010 in 705 vaccinated participants.
Seroconversion in vaccinated participants
Individuals with inclusion HI titre,1:40 Individuals with inclusion HI titre$1:40 All groups
All age groups 44.8% [38.2–51.6] 17.8% [14.5–21.6] 26.4% [23.2–29.8]
00–19 yo 40.0% [24.9–56.7] 22.2% [14.8–31.2] 27.0% [20.1–34.9]
20–39 yo 48.8% [37.9–59.9] 14.3% [9.2–19.4] 24.5% [20.3–31.0]
40–59 yo 45.1% [34.1–56.5] 22.6% [16.1–30.3] 30.7% [24.8–37.1]
60+yo 33.3% [11.8–61.6] 6.5% [1.4–17.9] 13.1% [5.8–24.2]
doi:10.1371/journal.pone.0061909.t007
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perform household duties [57]. From this perspective, in large
households, infected individuals are likely to be taken care of by
elderly family members, and transmission in this particular
instance may have occurred less frequently because these elderly
family members were less at risk of infection for this particular
virus.
Conclusion
Our study suggests that the profile of the 2009 A(H1N1)
pandemic in Laos was similar to that observed in other countries,
regardless of differences in environmental conditions, overall
socio-economic status or climatic specificities, with strong inde-
pendent epidemiological determinants characterizing this event.
Moreover, we detected pre-existing cross-reacting antibodies in
individuals over 60 yo, which could not have originated from
earlier multiple vaccination as has been suggested elsewhere. In a
developing country such as Laos, laboratory confirmation cannot
be performed for most cases, and healthcare seeking is far from
systematic. For this kind of particular event, using serological
cohorts is therefore one of the best ways of estimating infection
rates, and our study highlights the value of serological data as a
complement to clinical surveillance.
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